Development of novel clofarabine analogs for cancer therapy
US12103943B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 26, 2022 |
| Grant date | Oct 1, 2024 |
| Priority date | — |
| Expiry date | Oct 26, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/20
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present disclosure is concerned with Clofarabine analogs for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.